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Name Study	Design Methods Recruitment	Criteria Sample	Size	 Efficacy	Assesment	(Outcome)	
Measure
Findings
Akiyama	Y	(2015)
Japan
Single-center,	
prospective,	open	
labeled,	randomized	
comparitive	study
Single-center,	prospective,	open	labeled,	randomized	comparitivie	study.	
Patients	with	refactory	IC	were	randomly	divided	into	two	groups:	immediate	
injection	(group	A)	or	1-month	delayed	injection	(group	B)	of	botox	after	
allocation.		The	rate	of	treatment	response	(global	response	assessment	≥+1:	
slightly	improved),	and	changes	in	symptom	scores	and	frequency	volume	
chart	variables	were	compared	between	groups	1	month	after	allocation.	
Using	subjects	of	both	groups	as	a	single	cohort,	predictive	factors	for	
treatment	response	at
1	month	post-injection	and	the	duration	of	response	were	explored.
Between	September	2010	and	February	2012,	40	IC	patients	who	had	received	hydrodistention	at	
least	once	and	medical	treatment	of	one	or	more	oral	drugs	or	intravesical	agents,	yet	remained	to	
be	symptomatic,	six	points	or	higher	for	the	ICPI	and	ICSI	and	four	points	or	higher	for	VAS	for	pain.	
Diagnosis	for	IC	was	made	according	to	clinical	guidelines	for	IC	and	hypersensitive	bladder	
syndrome	according	to	the	NIDDK.	
	Full	analysis	carried	
out	using	34	patients	
(26	women,	8	men).	
Primary	end	point	-	response	rate	between	
two	groups	evaluated	by	GRA	a	onth	after	
allocation.	Patients	who	rated	the	efficacy	
as	better	than	+1	in	GRA	in	the	seven-point	
scale,	meaning	"slightly	improved"	
"improved"	or	"remarkably	improved"	
were	considered	responders	in	treatment.	
Secondary	end-points	were	symptom	
changes	from	baseline	compared	a	month	
after	allocation	by	OSSI/OSPI,	VAS	for	pain,	
QOL	based	on	the	QOL	index	of	the	
International	Prostate	Symptom	Score,	the	
Overactive	Bladder	Symptom	Score,	and	
the	frequency	volume	chart.	
All	the	symptom	scores	and	QOL	index	significantly	
improved	in	group	A	compared	with	group	B,	whereas	
none	of	the	FVC	variables	showed	significant	changes.		All	
symptomatic	parameters,	except	nocturia,	significantly	
improved	after	BoNT-A	treatment.	ICPI	-	p	<0.001,	ICSI	-	p	
<0.001,	VAS	-	p<0.001,	OABSS	-	p<0.001,	IPSS	-	p<0.01,	
QOL	-	p	<0.001,	Daytime	frequency	(times)	-	p<0.01,	
Nocturia	-	p:	0.17,	Average	voided	volume	-	p:	0.04,	
Maximum	voided	volume	-	p:	0.01	Additionally,	univariate	
analysis	showed	that	exposure	to	past	HD	more	than	
three	times	and	disease	duration	longer	than	6	years	were	
significant	factors	or	better	response.	
Manning	J	(2013)
Australia
Multicenter,	
prospective,	
randomized	double	
blind	study
Double-blind	study	of	54	women	with	severe,	refractory	IC	from	three	referral	
centers	whom	were	randomly	allocated	to	treatment	with	hydrodistention	+	
injection	of	normal	saline	or	to	hydrodistension	+	injection	of	AboBTXA.	The	
O'Leary	Sant	questionnaires,	and	bladder	diary	data	were	compared	between	
AboBTXA	and	control	patients	at	baseline,	and	at	3	months	of	follow-up.	
Patients	with	no	improvement	after	initial	treatment	had	access	at	minimum	
of	3	months	after	initial	to	AboBTXA	if	they	wished.	Patients	and	doctors	
remained	blinded	to	the	initial	treatment.	Measurements	were	made	beyond	
3	months,	but	no	further	randomised	comparison	was	possible	due	to	ability	
of	nonresponsive	patients	in	either	group	to	have	AboBTXA	treatment.	
From	January	2004	until	Feb	2009,	54	female	patients	with	longstanding	refractory	IC/BPS	were	
recruited	from	urogynaecology	clinics	at	three	centers.	All	study	participants	met	NIDDK	criteria,	
with	majority	having	had	multiple	prior	therapies.	Being	refractory	was	defined	as	having	failed	
two	or	more	recognized	treatments.	Study	participants	were	>18	years	of	age.	
54	female	patients Primary	outcome	measure:	OLS	(OLS	-	SI,	
OLS	-	PI)	
Secondary	outcome	measures	were	
frequencyand	nocturia	as	measured	by	
bladder	diary,	and	complications	such	as	
voiding	difficulty.	
OLS-PI	showed	significantly	greater	improvement	at	3	
months	in	the	AboBTXA	group	(p	=	0.04).	No	significant	
improvement	in	OLS-SI	or	total	OLS	scores	between	
baseline	and	3	months	for	AboBTXA	and	control	groups.	
12	patients	had	proven	UTI	detected	and	treated	at	some	
time	after	cytoscopy	and	injection	which	was	noted	to	be	
a	confounding	factor.	Once	the	analysis	was	performed	
without	UTI	patients,	there	was	an	overall	improvement	
in	AboBTXA	group	in	all	measurements,	including	total	
OLS	score	(p	=	0.02),	OLS-SI	(p	=	0.008,	OLS	-	PI	(p=0.08)	
and	question	4	of	the	OLS-PI	addressing	the	problem	of	
bladder	pain	(p=0.02)		There	was	no	significant	difference	
in	control	or	treatment	group	in	number	of	patients	
requesting	the	AboBTXA	treatment	after	3	months	(p	=	
0.16)	
Kuo	HC	(2013)
Taiwan
Prospective	
interventional	study
Thirty-one	consecutive	patients	with	IC/BPS	who	had	failed	conventional	
treatments	were	prospectively	enrolled	in	this	study	from	January	2006	to	
January	2010.	Patients	were	requested	to	keep	a	bladder	diary	to	asses	
frequency	and	nocturia.	Baseline	scores	were	assessed	for	O'Leary	Sant	
questionnaires	and	the	VAS	responses.	Video-urodynamic	studies	and	
pottasium	chloride	sensitivity	tests	were	preformed.	Patients	with	GRA	>2	
result	after	treatment	were	considered	to	have	a	successful	treatment	
outcome.	Patients	were	admitted	to	the	hospital	for	treatment	where	they	
received	intravesical	injection	of	botox,	followed	by	cytoscopic	
hydrodistention.	After	BoNT-A	injections,	a	catheter	remained	for	1	day	and	
patients	were	discharged	on	the	next	day.	Oral	antibiotics	were	prescribed	for	
7	days.	Patients	were	monitered	in	the	outpatient	clinic	2	weeks	later.	During	
each	follow-up	visit,	data	from	each	of	the	GRA,	diary,	OSS,	ICPI,	ICSI,	Pain	VAS	
were	recored.	Repeat	injections	were	repeated	6	months	after	the	first	
treatment,	and	patients	were	followed	up	in	the	same	way.	The	BoNT-A	
injection	was	repeated	every	6	months	for	four	times.	
Diagnosis	of	IC/BPS	was	established	based	on	characteristic	symptoms	and	cytoscopic	findings.	All	
patients	had	been	treated	with	at	least	2	of	the	following	medications:	oral	pentosanpolysulphate	
or	tricyclic	antidepressant,	intravesical	instillations	of	heparin	or	hyaluronic	acid	for	more	than	1	
year	-	but	symptoms	remained	unchanged.	
31	patients	(27	female	
and	4	male)	
Primary	end	point	-	Global	Response	
assesment	(GRA)	at	6	months	after	the	
fourth	BoNT-A	injection.	
Secondary	outcome	measures	were	ICSI,	
ICPI,	OSS<	VAS,	FBC,	Frequency,	Nocturia,	
PVR,	CBC,	FBC,	Qmas,	Volume
At	6	months	after	the	fourth	BoNT-A	injection,	19	of	31	
patients	(61%)	had	GRA	>2	and	12	had	a	GRA	<2.	In	the	
patients	with	GRA	>2,	OSS<	ICSI,	ICPI,	VAS,	FBC,	
frequency,	CBC,	and	glomerulation	grade	all	showed	
significant	improvement.	However,	no	significant	change	
in	measured	parameters	was	noted	in	patients	with	GRA	
<2.	Compared	with	the	changes	in	all	measured	
parameters	from	baseline	to	end-point,	patients	with	
GRA>2	had	significantly	greater	changes	in	OSS,	ICPI,	VAS,	
FBC,	and	CBC	than	those	with	a	GRA	<2.	The	theraputing	
effects	of	OSS,	VAS,	and	glomerulation	grade	were	
significantly	different	after	the	second	injection	between	
patients	with	GRA	>2	and	GRA	<2.	Among	the	patients	
who	were	not	satisfied	with	repeated	BoNT-A	injection,	5	
women	were	found	to	have	Hunner's	ulcer.	GRA	(p	=	
0.000),	OSS	(p=0.000),	VAS	(p=0.000),	FBC(p=0.000),	CBC	
(p=0.021),	PVR	(p=0.030)	Glomerulation	grades	(p=0.026)	
all	showed		significant	improvement	after	four	repeated	
injections.	
Lee	CL Prospective	
interventional	study
44	consecutive	patients	with	IC/BPS	who	had	failed	conventional	treatments	
were	prospectively	enrolled	in	this	study	from	January	2008	to	January	2012.	
Patients	were	requested	to	keep	a	bladder	diary	to	asses	frequency	and	
nocturia.	Baseline	scores	were	assessed	for	O'Leary	Sant	questionnaires	and	
the	VAS	responses.	Video-urodynamic	studies	and	pottasium	chloride	
sensitivity	tests	were	preformed.	Patients	with	GRA	>2	result	after	treatment	
were	considered	to	have	a	successful	treatment	outcome.	Patients	were	
admitted	to	the	hospital	for	treatment	where	they	received	intravesical	
injection	of	botox,	followed	by	cytoscopic	hydrodistention.	After	BoNT-A	
injections,	a	catheter	remained	for	1	day	and	patients	were	discharged	on	the	
next	day.	Oral	antibiotics	were	prescribed	for	7	days.	Patients	were	monitered	
in	the	outpatient	clinic	2	weeks	later.	During	each	follow-up	visit,	data	from	
each	of	the	GRA,	diary,	OSS,	ICPI,	ICSI,	Pain	VAS	were	recored.	Repeat	
injections	were	repeated	6	months	after	the	first	treatment,	and	patients	
were	followed	up	in	the	same	way.	The	BoNT-A	injection	was	repeated	every	6	
months	for	four	times.	
44	consecutive	patients	with	IC/BPS	who	had	experienced	conventional	treatment	failure	were	
prospectively	enrolled.	Diagnosis	was	stablished	based	on	characteristic	symptoms	and	cytoscopic	
findings.	All	patients	had	been	treated	with	at	least	2	of	following	medications:	oral	
pentosanpolysulphate	or	a	tricyclic	antidepressant	and	intravesical	instillations	of	heparin	or	
hyaluronic	acid	for	more	than	one	year	with	symptoms	remaining	unchanged.	
	Classified	as	ulcer(	n	=	
10) or	non-ulcer	(n	=	
30) -	total	40	women
Global	response	assessment	-	6	months	
after	the	4th	set	of	BoNT-A	injections	
OSS	score	including	ICSI	and	ICPI,	VAS	Pain	
score,	voiding	diary,	and	urodynamics	
variables
Patients	with	non-ulcer	IC/BPS	and	GRA	scores	>2	had	
significanty	decreased	ICSI,	ICPI,	OSS,	Pain	VAS,	frequency	
and	nocturia	episodes,	and	increased	FBC,	cystometric	
bladder	capacity.	Patients	with	non-ulcer	IC/BPS	and	GRA	
<2	also	had	decreased	ICSI,	ICPI,	OSS,	VAS,	frequency		
episodes,	and	increased	FBC	and	maximal	bladder	
capacity.	
Patients	with	non-ulcer	IC/BPS	and	GRA	scores	>2	had	
significanty	greater	improement	than	those	with	non-
ulcer	IC/BPS	and	GRA	scores	<2	for	ICSI	(P=0.007),	ICPI	
(P=0.016)	and	OSS	(P=0.004)	
Table 3. Comprehensive Summary Table on Literature Review of Onabotulinum Toxin A
Kuo	HC	(2012)
Taiwan
Prospective	
interventional	study
81	consecutive	patients	with	IC/PBS	who	failed	conventional	treatments	were	
prospectively	enrolled	in	this	study	from	July	2006	to	August	2010.	Patients	
were	requested	to	keep	a	bladder	diary	to	asses	frequency	and	nocturia.	
Baseline	scores	were	assessed	for	O'Leary	Sant	questionnaires	and	the	VAS	
responses.	Video-urodynamic	studies	and	pottasium	chloride	sensitivity	tests	
were	preformed.	Patients	with	GRA	>2	result	after	treatment	were	considered	
to	have	a	successful	treatment	outcome.	Patients	were	admitted	to	the	
hospital	for	treatment	where	they	received	intravesical	injection	of	botox,	
followed	by	cytoscopic	hydrodistention.	After	BoNT-A	injections,	a	catheter	
remained	for	1	day	and	patients	were	discharged	on	the	next	day.	Oral	
antibiotics	were	prescribed	for	7	days.	Patients	were	monitered	in	the	
outpatient	clinic	2	weeks	later.	During	each	follow-up	visit,	data	from	each	of	
the	GRA,	diary,	OSS,	ICPI,	ICSI,	Pain	VAS	were	recored.	Repeat	injections	were	
repeated	6	months	after	the	first	treatment,	and	patients	were	followed	up	in	
the	same	way.	The	BoNT-A	injection	was	repeated	every	6		months	until	
patients	felt	that	the	treatment	was	successful	up	to	4	injections.	
81	consecutive	patients	with	IC/BPS	who	had	experienced	conventional	treatment	failure	were	
prospectively	enrolled	from	July	2006	-	August	2010.	Diagnosis	was	established	based	on	
characteristic	symptoms	and	cytoscopic	findings	of	glomerulations,	petechia,	mucosal	fissue,	or	
ulceration.	All	patients	had	been	treated	with	at	least	one	of	the	following	medications:	oral	
pentosanpolysulphate,	intravesical	instillation	of	heparin,	hyaluronic	acid,	or	icyclic	antidepressant	
for	more	than	one	year	but	the	symptoms	remained	unchanged	or	had	relapsed.	They	were	
investigated	thoroughly	on	enrollment.	
81	patients	(71	
women,	and	10	men)	
OSS,	including	ICSI	and	ICPI.	VAS.	Video-
urodynamic	studies	at	baseline	and	end-
point.	Cystometric	studies.	GRA.	
OVerall,	the	GRA	and	symptom	variables	showed	
persistent	improvement	with	each	repeated	treatment	
when	baeline	of	each	successie	treatment	was	compared	
with	the	initial	study	baseline	level.
Among	81	patients,	20	received	single	injections,	19	
received	2	injections,	12	received	3	injections	and	30	
received	4	injections.	The	mean	sd	of	ICSI,	ICPI,	total	
scores,	VAS,	FBC,	and	daytime	frequency	all	showed	
significant	improvement	after	repeated	BoNT-A	treatment	
withd	ifferent	injections.	Significantly	better	success	rates	
were	noted	in	patients	who	received	4	repaeated	
injections	(p=0.0242)	and	3	injections	(P=0.05),	compared	
to	those	who	received	a	single	injection.	However,	there	
was	no	significant	difference	of	long-term	success	rates	
among	patients	who	received	2,	3,	and	4	injections.	
Chung	SD	(2012)
Taiwan
Prospective	non-
randomized	study
67	patients	with	IC/PBS	who	had	failed	conventional	treatments	were	
prospectively	enrolled	from	July	2007	to	August	2010.		atients	were	requested	
to	keep	a	bladder	diary	to	asses	frequency	and	nocturia.	Baseline	scores	were	
assessed	for	O'Leary	Sant	questionnaires	and	the	VAS	responses.	Video-
urodynamic	studies	and	pottasium	chloride	sensitivity	tests	were	preformed.	
Patients	with	GRA	>2	result	after	treatment	were	considered	to	have	a	
successful	treatment	outcome.	Patients	were	admitted	to	the	hospital	for	
treatment	where	they	received	intravesical	injection	of	botox,	followed	by	
cytoscopic	hydrodistention.	After	BoNT-A	injections,	a	catheter	remained	for	1	
day	and	patients	were	discharged	on	the	next	day.	Oral	antibiotics	were	
prescribed	for	7	days.	Patients	were	monitered	in	the	outpatient	clinic	2	
weeks	later.	During	each	follow-up	visit,	data	from	each	of	the	GRA,	diary,	
OSS,	ICPI,	ICSI,	Pain	VAS	were	recored.	Followup	was	recorded	at	3	months	
and	at	6	months	post	injection.
81	consecutive	patients	with	IC/BPS	who	had	experienced	conventional	treatment	failure	were	
prospectively	enrolled.	Diagnosis	was	established	based	on	characteristic	symptoms	and	
cytoscopic	findings	of	glomerulations,	petechia,	mucosal	fissue,	or	ulceration.	All	patients	had	
been	treated	with	at	least	one	of	the	following	medications:	oral	pentosanpolysulphate,	
intravesical	instillation	of	heparin,	hyaluronic	acid,	or	icyclic	antidepressant	for	more	than	one	year	
but	the	symptoms	remained	unchanged	or	had	relapsed.	They	were	investigated	thoroughly	on	
enrollment.	
67	patients	(60	women	
and	7	men)
OSS,	including	ICSI	and	ICPI.	VAS.	Video-
urodynamic	studies	at	baseline	and	end-
point.	Cystometric	studies.	GRA.	
Significant	improvement	was	shown	after	injection	
compared	to	baseline.	ICSI	(p=0.000),	ICPI	(p-0.000),	
VAS(p=0.000),	functional	bladder	capacity	(p=0.000),	GRA	
(p=0.000)
Giannantoni	A	(2010)
Italy
Prospective,	non-
randomized	study.
Patients	received	one	injection	of	BoNT/A	under	cystoscopic	guidance.	At	pre-	
and	3	months	post	treatment,	all	patients	underwent	an	urological	
assessment	(voiding	diary,	urodynamics),	a	pain	quanitification	on	VAS,	and	
evaluation	with	the	Hamilton	Anxiety	and	Hamilty	Depression	rating	scale,	and	
the	QoL	form.	
Refractory	pain	in	the	bladder	and	urethra,	vagina,	or	prineum	during	bladder	filling	or	after	
micturition;	frequency,	urgency	and	nocturia;	sterile	urine,	failure	of	all	previous	treatments	
including	oral	and	intravesical	therapies.	
12	patients	(all	
women)
VAS,	QoL,	HAM-A,	HAM-D,	Bladder	Diary Mean	VAS	score,	mean	daytime	and	nighttime	urinary	
frequency	all	decreased	significantly	(p<.01,	p<.01,	p<.01).	
All	domains	in	QoL	and	HAM-A	significantly	improved	
(p<.01,	p<.01).	All	domains	except	weight	and	sleep	
disoreders	significantly	improved	in	HAM-D	(p<.01)
Giannantoni	A	(2008)
Italy
Prospective,	
longitudinal	study
Under	short	general	anesthesia,	patients	were	given	injections	submucosally	
in	the	bladder	trigone	and	lateral	walls	under	cystoscopic	guidance.	A	voiding	
chart	and	the	visual	analog	scale	for	pain	were	used,	and	urodynamics	were	
performed	before	treatment	and	1,3,5,	and	12	months	later.	
Patients	with	refractory	pain	in	the	bladder	and	urethra,	vagina	or	perineum	durig	bladder	filling	or	
after	micturition	who	also	complained	of	frequency,	urgency,	and	nocturia.	All	previous	treaments,	
including	oral	and	intravesical	therapies,	had	failed	in	all	patients.
12	females	and	3	males.	Clinical	Evaluation,	VAS,	Cystoscopy	and	
urodynamics.	Local	and/or	systemic	side	
effects	were	noted.
Significant	improvements	in	daytime	and	night	time	
frequency	(p<.01,	p<.05)	VAS	(p<.01),	urodynamic	
parameters	(p<.01),	and	mean	maximum	cystometric	
capacity	(p<.01)	at	1	month	and	at	3	month.	
Bladder	pain	recurred	in	11	cases,	and	mean	VAS	score	
increased.	
At	1	year	-	bladder	pain	recurred	in	all	cases.	Clinical	and	
urodynamic	parameters	did	not	differ	with	respect	to	
those	at	baseline.	
Overall,	the	study	shows	significant	pain	relief	at	3	
months	in	86%	of	patients.	The	beneficial	effect	lasted	5	
months	in	about	30%	of	cases,	but	the	1-year	follow-up,	
pain	had	recurred	in	all.	
Smith	CP	(2004)
United	States/Poland
Prospective	
interventional	study
Patients	with	IC	under	short	general	anesthesia	or	sedation	were	injected	with	
Botulinum	toxin	through	a	cytoscope	submucosally	in	the	trigone	floor	of	the	
bladder.	Patients	were	evaluated	with	the	O'Leary-Sant	validated	IC	
questionnaire	or	with	voiding	charts	and	a	visual	analog	pain	scale	1	month	
postoperatively	and	at	subsequent	3	month	intervals.	Polish	patients	also	
underwent	pretreatment	and	post-treatment	urodynamic	evaluations
IC	was	diagnosed	according	to	the	NIDDK.	Previous	treatment	modalities,	including	oral	and	
intravesical	treatments	had	failed.	
12	females	-	6	in	US,	6	in	PolandICSI	 	ICPI,	VAS	
Urodynamic	parameters	were	assessed	in	
polish	patients
Overall,	9	(69%)	of	13	patients	noted	subjective	
improvement	after	BTX-A	treatment.	The	ICSI	and	ICPI	
mean	scores	improved	by	71%	and	69%	respectively	
(p<.05,	p<.05).	Daytime	frequency,	nocturia,	and	pain	by	
VAS	decreased	by	44$,	45%	and	79%	(P<0.01).	The	first	
desire	to	void	and	maximal	cystometric	capacity	increased	
by	58%	and	57%	respectively	(p<0.01).	
Table 3 Continued
